ATE439354T1 - Pharmazeutische salze von reboxetin - Google Patents

Pharmazeutische salze von reboxetin

Info

Publication number: ATE439354T1
Authority: AT; Austria
Prior art keywords: reboxetine; pharmaceutical salts; pharmaceutical; salts
Prior art date: 2002-06-17

Application number

AT03725195T

Other languages

English (en)

Inventor

Massimo Zampieri

Annalisa Airoldi

Alessandro Martini

Original Assignee

Pfizer Italia Srl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-17

Filing date

2003-06-04

Publication date

2009-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE439354(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-06-04 Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl

2009-08-15 Application granted granted Critical

2009-08-15 Publication of ATE439354T1 publication Critical patent/ATE439354T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Addiction (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Dermatology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT03725195T 2002-06-17 2003-06-04 Pharmazeutische salze von reboxetin ATE439354T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02077366		2002-06-17
PCT/EP2003/005261 WO2003106441A1 (en)	2002-06-17	2003-06-04	Pharmaceutical salts of reboxetine

Publications (1)

Publication Number	Publication Date
ATE439354T1 true ATE439354T1 (de)	2009-08-15

Family

ID=29724495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03725195T ATE439354T1 (de)	2002-06-17	2003-06-04	Pharmazeutische salze von reboxetin

Country Status (23)

Country	Link
US (2)	US20070010517A1 (de)
EP (1)	EP1515959B1 (de)
JP (1)	JP4563172B2 (de)
KR (1)	KR100779786B1 (de)
CN (2)	CN1662511B (de)
AR (1)	AR040222A1 (de)
AT (1)	ATE439354T1 (de)
AU (1)	AU2003227755B2 (de)
BR (1)	BR0311878A (de)
CA (1)	CA2489763C (de)
DE (1)	DE60328787D1 (de)
DK (1)	DK1515959T3 (de)
ES (1)	ES2328472T3 (de)
MX (1)	MXPA04011916A (de)
MY (1)	MY131231A (de)
NO (1)	NO329346B1 (de)
NZ (1)	NZ537023A (de)
PE (1)	PE20040565A1 (de)
PL (1)	PL375211A1 (de)
RU (1)	RU2286341C2 (de)
TW (1)	TWI267510B (de)
WO (1)	WO2003106441A1 (de)
ZA (1)	ZA200409624B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0319793D0 (en)	2003-08-22	2003-09-24	Lilly Co Eli	Pyridinylmorpholine derivatives
WO2005082869A1 (en) *	2004-02-20	2005-09-09	Pharmacia & Upjohn Company Llc	Method for the preparation of aryl ethers
US8580776B2 (en) *	2007-07-10	2013-11-12	The Board Of Trustees Of The University Of Illinois	Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) *	2008-09-06	2010-03-18	Bionevia Pharmaceuticals, Inc.	Novel forms of reboxetine
WO2018106825A1 (en) *	2016-12-06	2018-06-14	Tonix Pharmaceuticals Holding Corp.	Salts and polymorphs of esreboxetine
US12616702B2 (en)	2019-12-03	2026-05-05	Axsome Therapeutics, Inc.	Use of reboxetine to treat narcolepsy
US12565478B1 (en)	2025-01-21	2026-03-03	Axsome Therapeutics, Inc.	(S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2167407B (en) *	1984-11-22	1988-05-11	Erba Farmitalia	Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
JP2001517628A (ja) *	1997-09-23	2001-10-09	イーライ・リリー・アンド・カンパニー	注意欠陥／多動障害の治療法
UA57107C2 (uk) *	1997-09-23	2003-06-16	Елі Ліллі Енд Компані	Спосіб лікування розладу поведінки
UA56257C2 (uk) *	1997-09-23	2003-05-15	Елі Ліллі Енд Компані	Спосіб лікування неадекватної визивної поведінки
IT1305322B1 (it) *	1998-04-23	2001-05-04	Pharmacia & Upjohn Spa	Uso di reboxetina per il trattamento di disturbi nervosi
ES2246488T3 (es) *	1999-07-01	2006-02-16	PHARMACIA & UPJOHN COMPANY LLC	Reboxetina para tratar la migraña.

2003
- 2003-06-04 NZ NZ537023A patent/NZ537023A/en unknown
- 2003-06-04 CA CA002489763A patent/CA2489763C/en not_active Expired - Fee Related
- 2003-06-04 DK DK03725195T patent/DK1515959T3/da active
- 2003-06-04 AT AT03725195T patent/ATE439354T1/de not_active IP Right Cessation
- 2003-06-04 MX MXPA04011916A patent/MXPA04011916A/es active IP Right Grant
- 2003-06-04 EP EP03725195A patent/EP1515959B1/de not_active Expired - Lifetime
- 2003-06-04 KR KR1020047020412A patent/KR100779786B1/ko not_active Expired - Fee Related
- 2003-06-04 ES ES03725195T patent/ES2328472T3/es not_active Expired - Lifetime
- 2003-06-04 CN CN038139839A patent/CN1662511B/zh not_active Expired - Fee Related
- 2003-06-04 DE DE60328787T patent/DE60328787D1/de not_active Expired - Lifetime
- 2003-06-04 PL PL03375211A patent/PL375211A1/xx not_active Application Discontinuation
- 2003-06-04 RU RU2005100846/04A patent/RU2286341C2/ru not_active IP Right Cessation
- 2003-06-04 JP JP2004513273A patent/JP4563172B2/ja not_active Expired - Fee Related
- 2003-06-04 US US10/588,808 patent/US20070010517A1/en not_active Abandoned
- 2003-06-04 AU AU2003227755A patent/AU2003227755B2/en not_active Ceased
- 2003-06-04 CN CNA200810093308XA patent/CN101298440A/zh active Pending
- 2003-06-04 BR BR0311878-9A patent/BR0311878A/pt not_active IP Right Cessation
- 2003-06-04 WO PCT/EP2003/005261 patent/WO2003106441A1/en not_active Ceased
- 2003-06-11 MY MYPI20032183A patent/MY131231A/en unknown
- 2003-06-11 TW TW092115889A patent/TWI267510B/zh not_active IP Right Cessation
- 2003-06-13 AR ARP030102115A patent/AR040222A1/es unknown
- 2003-06-17 PE PE2003000594A patent/PE20040565A1/es not_active Application Discontinuation
2004
- 2004-11-29 ZA ZA200409624A patent/ZA200409624B/xx unknown
2005
- 2005-01-12 NO NO20050183A patent/NO329346B1/no not_active IP Right Cessation
2009
- 2009-05-21 US US12/469,780 patent/US20090291953A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR0311878A (pt)	2005-04-05
HK1077572A1 (zh)	2006-02-17
TWI267510B (en)	2006-12-01
MXPA04011916A (es)	2005-03-31
RU2005100846A (ru)	2005-06-10
EP1515959B1 (de)	2009-08-12
PL375211A1 (en)	2005-11-28
ZA200409624B (en)	2006-05-31
AR040222A1 (es)	2005-03-16
EP1515959A1 (de)	2005-03-23
JP4563172B2 (ja)	2010-10-13
ES2328472T3 (es)	2009-11-13
PE20040565A1 (es)	2004-09-02
CA2489763A1 (en)	2003-12-24
NZ537023A (en)	2006-09-29
NO329346B1 (no)	2010-10-04
WO2003106441A1 (en)	2003-12-24
NO20050183L (no)	2005-01-12
MY131231A (en)	2007-07-31
DK1515959T3 (da)	2009-11-02
CA2489763C (en)	2007-12-18
AU2003227755A1 (en)	2003-12-31
CN1662511A (zh)	2005-08-31
CN1662511B (zh)	2010-06-09
DE60328787D1 (de)	2009-09-24
AU2003227755B2 (en)	2009-01-15
US20090291953A1 (en)	2009-11-26
JP2005533791A (ja)	2005-11-10
KR100779786B1 (ko)	2007-11-28
KR20050019137A (ko)	2005-02-28
RU2286341C2 (ru)	2006-10-27
CN101298440A (zh)	2008-11-05
US20070010517A1 (en)	2007-01-11
TW200403230A (en)	2004-03-01

Legal Events

Date	Code	Title	Description
2010-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
NO2023030I1 (no)	2023-08-17	Apixaban and pharmaceutical acceptable salts thereof
DE50212273D1 (de)	2008-06-26	Pharmazeutische salze von 1-phenyl-3-dimethylamino-propan-verbindungen
DE60333294D1 (de)	2010-08-19	Kontrollierte verabreichung von arzneien
DE60201859D1 (de)	2004-12-16	Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
DE60324099D1 (de)	2008-11-27	Arzneistoffhaltiger tampon
ATE282428T1 (de)	2004-12-15	Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
EP1477403A4 (de)	2009-11-11	Arzneimittelversorgung
IS7946A (is)	2005-07-19	Lyf
ATE309789T1 (de)	2005-12-15	Darreichungsform von ibuprofen-natrium
CY2017048I1 (el)	2018-09-05	Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
DE60213592D1 (de)	2006-09-14	Flüssige pharmazeutische zusammensetzung
CY2018005I2 (el)	2018-06-27	Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
IS7571A (is)	2004-11-29	Ný lífeðlisfræðilega virk efni
DE60217390D1 (de)	2007-02-15	Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60336999D1 (de)	2011-06-16	Melatonin enthaltende pharmazeutische formulierung
DE60328787D1 (de)	2009-09-24	Pharmazeutische salze von reboxetin
FR2820311B3 (fr)	2003-01-17	Distributeur de medicament portatif
DE10291905D2 (de)	2004-05-27	Pharmazeutische Zusammensetzung
ATE350029T1 (de)	2007-01-15	Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
ATE443512T1 (de)	2009-10-15	Pharmazeutische zusammensetzung von piperazinderivaten
ATE349213T1 (de)	2007-01-15	Nasale pharmazeutische zusammensetzung von piribedil
DE10107261B4 (de)	2005-03-10	Pharmazeutische Zusammensetzung
PT1467737E (pt)	2006-08-31	Composicao farmaceutica orodispersivel de piribedil
ATA14072002A (de)	2005-10-15	Pharmazeutische zubereitung von diclofenac-natrium
SE0200022D0 (sv)	2002-01-07	Novel mode of drug administration